Metropolitan Life Insurance CO Chemo Centryx, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

41 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Jun 14, 2023	BUY	$22.17 - $51.8 $84,689 - $197,876	3,820 New	3,820 $197 Million
Q2 2022 Jun 20, 2023	BUY	$15.36 - $27.51 $58,675 - $105,088	3,820 New	3,820 $94,000
Q2 2022 Mar 30, 2023	BUY	$15.36 - $27.51 $9,000 - $16,120	586 Added 18.12%	3,820 $94,000
Q2 2022 Aug 11, 2022	BUY	$15.36 - $27.51 $9,000 - $16,120	586 Added 18.12%	3,820 $95,000
Q1 2022 Jun 20, 2023	BUY	$22.22 - $39.12 $71,859 - $126,514	3,234 New	3,234 $81,000
Q1 2022 Mar 30, 2023	SELL	$22.22 - $39.12 $261,507 - $460,403	-11,769 Reduced 78.44%	3,234 $81,000
Q1 2022 May 12, 2022	SELL	$22.22 - $39.12 $261,507 - $460,403	-11,769 Reduced 78.44%	3,234 $81,000
Q4 2021 Jun 21, 2023	BUY	$18.38 - $40.5 $275,755 - $607,621	15,003 New	15,003 $546,000
Q3 2021 Jun 21, 2023	BUY	$13.18 - $19.83 $197,739 - $297,509	15,003 New	15,003 $256,000
Q2 2021 Jun 21, 2023	BUY	$9.59 - $50.88 $143,878 - $763,352	15,003 New	15,003 $200,000
Q2 2021 Mar 30, 2023	BUY	$9.59 - $50.88 $11,479 - $60,903	1,197 Added 8.67%	15,003 $200,000
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $143,744 - $762,640	14,989 Added 107064.29%	15,003 $201,000
Q1 2021 Jun 26, 2023	BUY	$49.53 - $68.4 $683,811 - $944,330	13,806 New	13,806 $707 Million
Q1 2021 Mar 30, 2023	SELL	$49.53 - $68.4 $32,144 - $44,391	-649 Reduced 4.49%	13,806 $707,000
Q1 2021 May 14, 2021	SELL	$49.53 - $68.4 $715,262 - $987,764	-14,441 Reduced 99.9%	14 $707,000
Q4 2020 Jun 22, 2023	BUY	$47.25 - $65.16 $682,998 - $941,887	14,455 New	14,455 $895,000
Q4 2020 Mar 30, 2023	BUY	$47.25 - $65.16 $9,072 - $12,510	192 Added 1.35%	14,455 $895,000
Q4 2020 Feb 16, 2021	BUY	$47.25 - $65.16 $9,072 - $12,510	192 Added 1.35%	14,455 $895,000
Q3 2020 Jun 26, 2023	BUY	$46.35 - $61.69 $661,090 - $879,884	14,263 New	14,263 $781,000
Q3 2020 Mar 30, 2023	BUY	$46.35 - $61.69 $30,359 - $40,406	655 Added 4.81%	14,263 $781,000
Q3 2020 Nov 13, 2020	BUY	$46.35 - $61.69 $30,359 - $40,406	655 Added 4.81%	14,263 $782,000
Q2 2020 Jun 26, 2023	BUY	$38.58 - $65.07 $524,996 - $885,472	13,608 New	13,608 $783,000
Q2 2020 Mar 30, 2023	BUY	$38.58 - $65.07 $33,873 - $57,131	878 Added 6.9%	13,608 $783,000
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $33,873 - $57,131	878 Added 6.9%	13,608 $783,000
Q1 2020 Jul 12, 2023	BUY	$32.73 - $50.78 $425,391 - $659,987	12,997 New	12,997 $522,000
Q4 2019 Jul 12, 2023	BUY	$6.81 - $39.55 $86,691 - $503,471	12,730 New	12,730 $503,000
Q4 2019 Mar 30, 2023	SELL	$6.81 - $39.55 $15,329 - $89,027	-2,251 Reduced 15.03%	12,730 $503,000
Q4 2019 Feb 14, 2020	SELL	$6.81 - $39.55 $15,329 - $89,027	-2,251 Reduced 15.03%	12,730 $503,000
Q3 2019 Jul 12, 2023	BUY	$6.47 - $8.96 $96,927 - $134,229	14,981 New	14,981 $101,000
Q3 2019 Mar 30, 2023	BUY	$6.47 - $8.96 $39,965 - $55,345	6,177 Added 70.16%	14,981 $101,000
Q3 2019 Nov 14, 2019	BUY	$6.47 - $8.96 $39,965 - $55,345	6,177 Added 70.16%	14,981 $102,000
Q2 2019 Jul 12, 2023	BUY	$8.31 - $14.85 $83,997 - $150,103	10,108 New	10,108 $94,000
Q1 2019 Jul 13, 2023	BUY	$10.01 - $13.89 $88,128 - $122,287	8,804 New	8,804 $122,000
Q1 2019 Mar 30, 2023	BUY	$10.01 - $13.89 $88,128 - $122,287	8,804 New	8,804 $122,000
Q1 2019 May 16, 2019	SELL	$10.01 - $13.89 $336,095 - $466,370	-33,576 Reduced 79.23%	8,804 $122,000
Q1 2019 May 15, 2019	BUY	$10.01 - $13.89 $336,095 - $466,370	33,576 Added 381.37%	42,380 $730,000
Q4 2018 Jul 13, 2023	BUY	$9.15 - $12.26 $80,556 - $107,937	8,804 New	8,804 $96,000
Q4 2018 Feb 14, 2019	BUY	$9.15 - $12.26 $63,409 - $84,961	6,930 Added 369.8%	8,804 $96,000
Q3 2018 Jul 13, 2023	BUY	$10.49 - $13.72 $91,420 - $119,569	8,715 New	8,715 $110 Million
Q3 2018 Nov 14, 2018	SELL	$10.49 - $13.72 $71,762 - $93,858	-6,841 Reduced 78.5%	1,874 $24,000
Q1 2018 May 15, 2018	BUY	$5.9 - $14.99 $51,418 - $130,637	8,715 New	8,715 $0

Others Institutions Holding CCXI

# of Institutions

Shares Held

66.3K

Call Options Held

Put Options Held

View Full List

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account